

A peer-reviewed version of this preprint was published in PeerJ on 23 April 2015.

[View the peer-reviewed version](https://doi.org/10.7717/peerj.882) (peerj.com/articles/882), which is the preferred citable publication unless you specifically need to cite this preprint.

Biswas KH, Badireddy S, Rajendran A, Anand GS, Visweswariah SS. 2015. Cyclic nucleotide binding and structural changes in the isolated GAF domain of *Anabaena* adenylyl cyclase, CyaB2. PeerJ 3:e882 <https://doi.org/10.7717/peerj.882>

Distinct binding modes and structural changes induced by cAMP and cGMP in the GAF domain of *Anabaena* adenylyl cyclase, CyaB2

GAF domains are a large family of regulatory domains, and a subset are found associated with enzymes involved in cyclic nucleotide (cNMP) metabolism such as adenylyl cyclases and phosphodiesterases. CyaB2, an adenylyl cyclase from *Anabaena*, contains two GAF domains in tandem at the N-terminus and an adenylyl cyclase domain at the C-terminus. Cyclic AMP, but not cGMP, binding to the GAF domains of CyaB2 increases the activity of the cyclase domain leading to enhanced synthesis of cAMP. Here we show that the isolated GAFb domain of CyaB2 can bind both cAMP and cGMP, and enhanced specificity for cAMP is observed only when both the GAFa and the GAFb domains are present in tandem (GAFab domain). *In silico* docking and mutational analysis indicated distinct modes of binding of cAMP and cGMP to the GAFb domain. Structural changes associated with ligand binding to the GAF domains could not be detected by the highly sensitive Bioluminescence Resonance Energy Transfer (BRET) experiments. Amide hydrogen-deuterium exchange mass spectrometry (HDXMS) experiments, however, revealed the structural basis for cAMP-induced allosteric regulation of the GAF domains, and differences in the structural changes induced by cAMP and cGMP binding to the GAF domain. Thus, our results provide an insight into structural mechanisms of ligand binding to GAF domains in general, which can be utilized in developing molecules that modulate the allosteric regulation by GAF domains in pharmacologically relevant proteins.[b]

Distinct binding modes and structural changes induced by cAMP and cGMP in the GAF domain of *Anabaena* adenylyl cyclase, CyaB2

Authors: Kabir Hassan Biswas^{1,3}, Suguna Badireddy², Ganesh Srinivasan Anand² and Sandhya S Visweswariah¹

Affiliations:

¹ Department of Molecular Reproduction, Development and Genetics, Indian Institute of Science, Bangalore – 560012, India;

² Department of Biological Sciences, National University of Singapore, Singapore – 117543, Singapore

³ Current affiliation: Mechanobiology Institute, National University of Singapore, Singapore 117411, Singapore

Corresponding authors:

Sandhya S Visweswariah, Department of Molecular Reproduction, Development and Genetics, Indian Institute of Science, Bangalore – 560012, India, Tel: +91 80 22932542/23601522, email: sandhya@mrdg.iisc.ernet.in

Kabir Hassan Biswas, Mechanobiology Institute, National University of Singapore, Singapore 117411, Singapore, Tel: +65 66018983, email: mbikhb@nus.edu.sg

Keywords: BRET; cAMP; cGMP; cyclases; GAF; HDXMS; ligand; phosphodiesterases; structural changes

Abbreviations: BRET, bioluminescence resonance energy transfer; cAMP, adenosine 3', 5' – cyclic monophosphate; cGMP, guanosine 3', 5' –cyclic monophosphate; GAF, cGMP-specific and -regulated cyclic nucleotide phosphodiesterase, Adenylyl cyclase, and *E. coli* transcription factor FhlA; HDXMS, amide hydrogen/deuterium exchange mass spectrometry;

ABSTRACT

GAF domains are a large family of regulatory domains, and a subset are found associated with enzymes involved in cyclic nucleotide (cNMP) metabolism such as adenylyl cyclases and phosphodiesterases. CyaB2, an adenylyl cyclase from *Anabaena*, contains two GAF domains in tandem at the N-terminus and an adenylyl cyclase domain at the C-terminus. Cyclic AMP, but not cGMP, binding to the GAF domains of CyaB2 increases the activity of the cyclase domain leading to enhanced synthesis of cAMP. Here we show that the isolated GAFb domain of CyaB2 can bind both cAMP and cGMP, and enhanced specificity for cAMP is observed only when both the GAFa and the GAFb domains are present in tandem (GAFab domain). *In silico* docking and mutational analysis indicated distinct modes of binding of cAMP and cGMP to the GAFb domain. Structural changes associated with ligand binding to the GAF domains could not be detected by the highly sensitive Bioluminescence Resonance Energy Transfer (BRET) experiments. Amide hydrogen-deuterium exchange mass spectrometry (HDXMS) experiments, however, revealed the structural basis for cAMP-induced allosteric regulation of the GAF domains, and differences in the structural changes induced by cAMP and cGMP binding to the GAF domain. Thus, our results provide an insight into structural mechanisms of ligand binding to GAF domains in general, which can be utilized in developing molecules that modulate the allosteric regulation by GAF domains in pharmacologically relevant proteins.

INTRODUCTION

GAF domains (cGMP-specific and -regulated cyclic nucleotide phosphodiesterase, Adenylyl cyclase, and *E. coli* transcription factor FhlA) are a family of protein domains that regulate the function of a variety of domains with which they are associated (Aravind & Ponting 1997; Charbonneau et al. 1990). They represent one of the largest families of small molecule-binding regulatory domains, and are found in organisms in all three kingdoms of life (Anantharaman et al. 2001; Martinez et al. 2002a). GAF domains (~150 amino acids long) are found associated with additional signaling domains such as the PAS, Sigma54_activat, helix-turn-helix (HTH), PEP_utilizers_C, GGDEF, EAL, HisKA and phosphodiesterase domains (Aravind & Ponting 1997; Finn et al. 2010). GAF domains can bind a variety of ligands including tetrapyrroles, formate, haeme, bilin and cyclic nucleotides (Anantharaman et al. 2001; Zoraghi et al. 2004). Although the sequences of these domains have diverged substantially due to their long evolutionary history (Aravind et al. 2002), a motif of five residues (NKFDE) is conserved in most of the characterized cNMP-binding GAF domains (Zoraghi et al. 2004).

The structures of a number of cNMP-binding GAF domains have been solved by X-ray crystallography and NMR. These include the GAF domains in the cGMP-stimulated, cAMP phosphodiesterase, PDE2 (Martinez et al. 2002b), *Anabaena* CyaB2 adenylyl cyclase (Martinez et al. 2005) and the cGMP-stimulated, cGMP-specific PDE5 (Heikaus et al. 2009; Pandit et al. 2009; Russwurm et al. 2011; Wang et al. 2010). A common structural feature shared by these GAF domain is the presence of six central anti-parallel β -sheets flanked by α -helices on both sides (Heikaus et al. 2009). The β -sheets form a curved plane that separates the α -helices into two groups. The curved plane of the antiparallel β -sheets serves as the base of the ligand-binding pocket, and the rest of the ligand-binding pocket is covered by helices α 3, α 4, and some loop

1 regions. Helices $\alpha 2$ and $\alpha 5$ are present on the opposite side of the ligand-binding pocket. In
2 CyaB2, helix $\alpha 2$ connects the GAFb domain to N-terminal GAFa domain in CyaB2 and helix $\alpha 5$
3 connects the GAF domain to the C-terminal PAS and adenylyl cyclase effector domains. Cyclic
4 AMP is buried within the ligand-binding pocket (Fig. 1A), and important residues in the ligand
5 binding pocket that interact with cAMP include Arg 291 (H-bond with N1 of cAMP), Thr 293
6 (H-bond with N6 and N7 of cAMP), Asp 356 and Asn 359 (water mediated H-bond with N3 of
7 cAMP), and Ile 308 (hydrophobic contact to the adenine ring of cAMP).

8 Most of the cNMP binding GAF domains show high specificity towards cNMPs. But the basis
9 for nucleotide selectivity of some GAF domains still remains unknown. Substitution of a region
10 of the CyaB1 GAFb domain with that of a corresponding region in the cGMP-binding GAF
11 domain of PDE2, allowed CyaB1 to show cGMP-enhanced adenylyl cyclase activity. However,
12 the converse experiment in which amino acids in the PDE2 GAF domain were replaced with
13 those from CyaB1 did not lead to altered specificity (Linder et al. 2007). In addition, structural
14 studies combined with mutational analysis of the GAFa domain of PDE5 suggested that a key
15 residue (Asp 164) allowed the discrimination between cAMP and cGMP (Heikaus et al. 2008).

16
17 In the present study, we show by direct binding assays that the specificity of nucleotide binding
18 is reduced in an isolated GAF domain, as compared to the tandem GAFab domains of CyaB2. *In*
19 *silico* docking experiments suggested that the GAF domain could bind cGMP in an orientation
20 distinct from cAMP, and mutational analysis coupled with HDXMS identified diverse structural
21 changes induced by cAMP and cGMP.

MATERIALS AND METHODS

Generation of various GAF domain constructs and mutagenesis

The nucleotide sequence of the GAFb domain of CyaB2 from *Anabaena* sp. PCC 7120 spanning residues L270 to L431 was amplified by PCR from the full-length CyaB2 gene cloned into pQE30 plasmid (pQE30-CyaB2 (Bruder et al. 2005)) using primers GAFbf793 (5' CTGGGATCCGGTACCCTGGATTTAGAAGATACCC 3') and GAFbr1279 (5' ACACTCGAGCGATATCTAAAGCCACCCCGGC 3'). The PCR product was directly cloned into pGEM-T-Easy vector (Promega) to generate the plasmid pGEM-T-GAFb and insert was sequenced. To generate a GST fusion protein for cyclic nucleotide binding experiments and His₆-tagged protein for HDXMS experiments, the GAFb nucleotide sequence was released and subcloned into pGEX-6p-1 plasmid vector (GE Healthcare) and pPRO-Ex-B plasmid vector (Invitrogen), respectively, using *Bam*HI and *Xho*I sites, resulting in the pGEX-6p-1-GAFb and pPRO-Ex-GAFb plasmid. To generate a BRET-based sensor, the GAFb gene fragment was released and subcloned into the pGFP²-MCS-Rluc plasmid vector (PerkinElmer Life Sciences) using *Kpn*I and *Eco*RV sites, resulting in the pGFP²-GAFb-Rluc plasmid. The I308A mutation in the GAFb domain was introduced using single primer method (Shenoy & Visweswariah 2003) using the primer GAFb_CyaB2(I308A) (5' GGACGAAAGCTACCCAAGATAATGGTTCTACTAAGG 3') and the mutation was confirmed by sequencing.

The nucleotide sequence of the tandem GAFab domains of CyaB2 spanning residues S77 to L431 was amplified by PCR from the full-length CyaB2 gene cloned into pQE30 plasmid (pQE30-CyaB2 (Bruder et al. 2005)) using primers GAFaf216 (5' GTCAATGTTGGGATCCCACGGTACCGAAAATATCCTGC 3') and GAFbr1279. The PCR

1 product was directly cloned into pGEM-T-Easy vector (Promega) and sequenced. To express a
2 GST fusion protein, the tandem GAFab domain gene fragment was subcloned into pGEX-6p-1
3 plasmid vector (GE Healthcare) using *Bam*HI and *Xho*I sites, resulting in the pGEX-6p-1-GAFab
4 plasmid. To generate a BRET-based sensor construct, the tandem GAFab domain gene fragment
5 was subcloned into the pGFP²-MCS-Rluc plasmid vector (PerkinElmer Life Sciences) using
6 *Eco*RV and *Xho*I sites, resulting in the generation of pGFP²-GAFab-Rluc plasmid.

7 The nucleotide sequence encoding residues M1 to L431 was PCR amplified from the full-length
8 CyaB2 gene cloned into pQE30 plasmid (pQE30-CyaB2 (Bruder et al. 2005)) using primers
9 GAFab_CyaB2f1 (5'ATATGGATCCGGTACCATGTCATTGCAACAGCG 3') and
10 GAFb_CyaB2r1271 (5'ACACTCGAGCGATATCTAAAGCCACCCCGGC 3') and subcloned
11 into pGEX-6p-1 plasmid vector (GE Healthcare) using *Bam*HI and *Xho*I sites, resulting in the
12 pGEX-6p-1-NterGAFab plasmid and sequenced. To generate a BRET-based sensor construct
13 containing N-terminal regional along with tandem GAFab domain (NterGAFab), gene fragment
14 encoding NterGAFab domain was subcloned into the pGFP²-MCS-Rluc plasmid vector
15 (PerkinElmer Life Sciences) using *Eco*RV and *Xho*I sites, resulting in the generation of pGFP²-
16 NterGAFab-Rluc plasmid.

17 **Expression and purification of the GAF domain constructs of CyaB2**

18 To express and purify GST fusion proteins, *E. coli* BL21 (DE3) cells were transformed with
19 specific plasmid and cells were induced using 100 μ M IPTG at 37°C for 3 h. Cells were
20 collected by centrifugation and cell pellet was resuspended in lysis buffer containing 50 mM Tris
21 (pH 8.2 at 4 °C), 100 mM NaCl, 10% glycerol, 2 mM PMSF, 1 mM benzamidine. Cells were
22 lysed by sonication and lysate was centrifuged at 30,000 g for 30 min at 4 °C. Supernatant was
23 collected and interacted with pre-equilibrated glutathione sepharose 4B beads (Amersham

Pharmacia Biotech) at 4 °C for 1 h. Post interaction, beads were washed with buffer containing 50 mM Tris (pH 8.2 at 4 °C), 100 mM NaCl, 0.1% TritonX-100 followed by three washes with buffer containing 50 mM Tris (pH 8.2 at 4 °C), 100 mM NaCl, 10% glycerol. The protein-bound GSH beads were resuspended in buffer containing 25 mM HEPES, 100 mM NaCl and 10% glycerol and stored at 4°C till further use.

To express the His₆-GAF protein, *E. coli* BL21DE3 *cyc*⁻ cells were transformed with pPRO-Ex-B-GAFb plasmid DNA and induced with 500 µM IPTG for 3 h at 37°C (Nambi et al. 2010). Cells were harvested by centrifugation at 6000 g for 20 min and the cell pellet was resuspended in lysis buffer [20 mM Tris-HCl (pH 7.5), 100 mM NaCl, 5 mM β-mercaptoethanol, 5 mM imidazole and EDTA free protease inhibitor tablet (Roche)]. Cells were lysed using a sonicator (Misonix) and centrifuged at 17,000 g at 4 °C for 40 min. The supernatant was collected and incubated with Talon resin (Clontech laboratories, Mountain View, CA) at 4 °C for 1 h. The resin was then transferred into columns (Bio Rad). Washes were performed with both lysis buffer and wash buffer (Lysis buffer with 10mM imidazole) followed by elution buffer containing lysis buffer with 150 mM imidazole. Further purification was achieved by size-exclusion chromatography [Superdex200 column, AKTA system (GE Healthcare)].

Cyclic nucleotide binding assays

Cyclic nucleotide binding assays were carried out essentially as described earlier (Sopory et al. 2003) using 1 µg of purified GST fusion proteins bound to glutathione beads in a 50 µL reaction volume, in buffer containing 25 mM HEPES, 100 mM NaCl, 10% glycerol and 200 µM PMSF in the presence of varying concentration of [³H]-cAMP either in the absence or presence of unlabeled cAMP. Reactions were incubated at 37 °C for 1 h and then filtered through GF/C filters (Whatman), which were then washed with 6 mL of ice-cold washing buffer (10 mM Tris,

pH 7.5, 100 mM NaCl and 10% glycerol). The filters were then dried and radioactivity was measured by scintillation counting in scintillation cocktail (1:1, 2-methoxy ethanol: toluene, 5 g/l PPO).

Docking of cyclic nucleotides to the GAFb domain of CyaB2

Docking was performed using AutoDock (Version 3.0.5) (Morris 1998) implemented using AutoDock Tools (Molecular Graphics Laboratory). The performance of AutoDock was tested by first docking cAMP, and then cGMP, into the GAFb domain. For docking cNMPs to the GAFb domain of CyaB2, the atomic structure comprising residues Leu270 to Leu431 of CyaB2 (PDB: 1YKD) was selected to be used as the macromolecule (Martinez et al. 2005). All water molecules and cAMP were removed from the structure before docking. Atomic coordinates of cAMP and cGMP were generated from the SMILES structure descriptor format, available in the PubChem database, using Online SMILES Translator and Structure File Generator (<http://cactus.nci.nih.gov/services/translate/>). Charges were added to the atoms and the final structure file for AutoDock was prepared using the Dundee PRODRG2 Server (<http://davapc1.bioch.dundee.ac.uk/programs/prodrg/>) (Schuttelkopf & van Aalten 2004). Atomic volume and solvation parameters were assigned to the protein molecule using default values. Polar hydrogen atoms were added and Kollman charges were assigned using the built in function in AutoDock Tools. Grids were used at a spacing of 0.375 Å covering the cAMP binding site in a cube of 90 x 90 x 90 grid points with the grid center placed near the phosphate group of cAMP as found in the crystal structure. Docking was performed with a Lamarckian genetic algorithm with a total of 50 genetic algorithm runs for cAMP and 20 for cGMP. Other docking parameters were: population size = 50, mutation rate = 0.02, crossover rate = 0.8, number of genetic algorithm evaluations = 250000, number of genetic algorithm generations =

2700000 and genetic algorithm elitism = 1. Results were analyzed using command get_docked and Pymol.

Cell culture and transfection

Human embryonic kidney (HEK) 293T cells were maintained in Dulbecco's modified Eagle's media (DMEM) with 10% fetal calf serum, 120 mg/L penicillin and 270 mg/L streptomycin at 37 °C in a 5% CO₂ humidified incubator. Transfection was performed with polyethyleneimine lipid according to manufacturers' protocols. Expression of proteins was monitored by Western Blot analysis using an antibody raised in rabbit against the Rluc protein and described below.

Generation of polyclonal antibody against Rluc

Polyclonal antibodies against Rluc protein was raised in rabbits using His₆-Rluc protein essentially as described previously (Bakre et al. 2000b). Rluc gene was released from pRluc-N1 plasmid vector (PerkinElmer Life Sciences) and subcloned into pPRO-Ex-C (Invitrogen) using *Bam*HI and *Xba*I sites to generate the pPRO-Ex-C-Rluc plasmid. To express the protein, *E. coli* BL21DE3 were transformed with pPRO-Ex-C-Rluc plasmid and induced with 100 µM IPTG. His₆-Rluc protein formed inclusion bodies. Protein aggregates was solubilized using urea and was used for antibody generation. The primary dose of immunogen (~500 µg) was in Freund's complete adjuvant and booster dose of immunogen (~250 µg) was in Freund's incomplete adjuvant. The presence of antibody was detected by ELISA and Western Blot analysis.

In vitro BRET assays

1 All BRET assays were performed using the BRET² assay components i.e. acceptor - GFP², donor
2 - Rluc and Rluc substrate - Coelenterazine 400a. In vitro BRET assays were performed as
3 described previously (Biswas et al. 2008; Biswas & Visweswariah 2011). HEK 293T cells
4 transfected with appropriate plasmids were lysed in a buffer of 50 mM HEPES (pH 7.5),
5 containing 2 mM EDTA, 1 mM dithiothreitol, 100 mM NaCl, 10 mM sodium pyrophosphate, 80
6 μ M β -glycerophosphate, 1 mM benzamidine, 1 μ g/mL aprotinin, 1 μ g/mL leupeptin, 5 μ g/mL
7 soybean trypsin inhibitor, 100 μ M sodium orthovanadate and 10 % glycerol. Following brief
8 sonication, the lysates was centrifuged at 13,000 g and the cytosol was collected. Aliquots of the
9 cytosol were incubated with 1 mM cNMP in buffer of 50 mM HEPES, pH 7.5, containing 100
10 mM NaCl in a total volume of 40 μ L, at 37 °C for 10 min. Coelenterazine 400a (Molecular
11 Imaging Products) was added to a final concentration of 5 μ M and emissions were collected for
12 0.8 s in a Victor³ microplate reader (Perkin Elmer). Emission filters used for Rluc and GFP²
13 emission were 410 nm (bandpass 80 nm) and 515 nm (bandpass 30 nm), respectively. BRET was
14 calculated as the ratio of GFP emission per second to Rluc emission per second, and the average
15 of three such measurements is reported.

16 Cellular BRET assays

17 HEK 293T cells were transfected with pGFP²-GAFb-Rluc plasmid in 10 cm tissue culture
18 dishes. Forty eight hours post transfection, medium was removed, and monolayers treated with
19 Dulbecco's phosphate buffered saline containing 5 mM EDTA for 5 min at 37 °C in the
20 incubator following which the EDTA solution was removed, and cells resuspended in phenol-red
21 free DMEM, containing 10% fetal calf serum. Cells ($\sim 10^5$) were then treated with 100 μ M of
22 either forskolin (for 5 min) or sodium nitroprusside (for 2 min). BRET was determined as
23 mentioned in the previous section.

Intracellular cNMP estimation

Intracellular levels of cyclic nucleotide monophosphates (cNMP) were measured from the cells used for BRET measurements, or similarly transfected and treated cells. Cells were lysed in 0.1 N HCl and cNMP was measured by radioimmunoassay as described earlier (Bakre et al. 2000a).

HDXMS of the GAFb domain of CybB2

The cAMP-free GAFb domain purified by size exclusion chromatography was concentrated to 50 μ M using vivaspin concentrators (Sartorius Stedim Biotech GmbH, Goettingen, Germany). Samples were prepared by adding 1 mM cAMP and cGMP each to 50 μ M apo GAFb domain protein. 2 μ L each of apo, cAMP-, or cGMP-bound GAFb domain in 20 mM Tris-HCl (pH 7.5), 100 mM NaCl and 5 mM buffer were diluted and incubated with 18 μ L of D₂O (99.90%) (Fluka BioChemika, Buchs, Switzerland) resulting in a final deuterium concentration of 90%. Hydrogen-deuterium exchange was carried out at 20 °C for various time points (0.5, 1, 2, 5 and 10 min). The exchange reaction was quenched by adding 40 μ L of prechilled quench buffer (0.1% trifluoroacetic acid (Fluka BioChemika, Buchs, Switzerland) to get a final pH read of 2.5. A 50 μ L aliquot of the quenched sample was then injected on to a chilled nanoUPLC sample manager (beta test version, Waters, Milford, MA) as previously described (Badireddy et al. 2011; Wales et al. 2008). Peptides were detected and sequenced and mass was measured on a Synapt HDMS mass spectrometer (Waters, Manchester, UK) acquiring in the MS^E mode, a nonbiased, nonselective CID method (Bateman et al. 2002; Li et al. 2009; Shen et al. 2009; Silva et al. 2005).

Sequence identifications were made from MS^E data from undeuterated samples using ProteinLynx Global Server 2.4 (beta test version) (Waters, Milford, MA) (Geromanos et al.

2009; Li et al. 2009) and searched against sequence of GAFb domain with no enzyme specified and no modifications of amino acids. Identifications were only considered if they appeared at least twice out of three replicate runs. The precursor ion mass tolerance was set at <10 ppm and fragment ion tolerance was set at <20 ppm. Only those peptides that satisfied the above criteria through Database search pass 1 were selected and are listed in Table 1 (Li et al. 2009). The default criterion for false positive identification (Value = 4) was applied. These results showed that MS^E data searched with PLGS 2.4 maximized identification of peptides and were used for deuterium exchange analysis. These identifications were mapped to subsequent deuteration experiments using prototype custom software (HDX browser, Waters, Milford). Data on each individual peptide at all periods were extracted using this software, and exported to HX-Express (Weis et al. 2006) for analysis. A total number of 38 peptide fragments yielded primary sequence coverage of 96%. Continuous instrument calibration was carried out with Glu-fibrinogen peptide at 100 fmol/μl. We also visually analyzed the data to ensure only well resolved peptide isotopic envelopes were subjected to quantitative analysis.

Statistical analysis

All experimental data were analyzed using GraphPad Prism and represent the mean ± S.E.M.

RESULTS

GAFb domain of CyaB2 binds both cAMP and cGMP

GAF domains associated with enzymes such as nucleotide cyclases and phosphodiesterases are often present in tandem repeats (Bruder et al. 2006; Schultz 2009). In the case of CyaB2, both the GAFa and GAFb domains bind cAMP. However, binding of cAMP to the GAFb domain is

likely to trigger the conformational changes in the protein that enhance adenylyl cyclase activity. We therefore tested if an isolated GAFb domain of CyaB2 was able to bind ligand by direct radiolabeled cyclic nucleotide binding assays. The isolated GAFb domain encompassing residues Leu 270 to Leu 431 fused to GST was expressed in bacteria and purified. High affinity cAMP binding, with a K_D of $0.8 \pm 0.2 \mu\text{M}$ (Fig. 1B & C) was observed, and was similar to the EC_{50} value ($\sim 1.3 \mu\text{M}$) reported previously from assays monitoring cAMP-mediated activation of a related adenylyl cyclase domain (Bruder et al. 2005). This result along with our previous studies using the isolated GAFa domain of PDE5 (Biswas et al. 2008) establishes that isolated GAF domains are able to bind their respective ligand even in the absence of the second GAF domain, or other associated catalytic domains.

Previous studies have shown that the GAF domains associated with nucleotide cyclases and phosphodiesterases show specificity in binding either cAMP or GMP. For instance, the GAFa domain of PDE5 specifically binds cGMP (Biswas et al. 2008; Sopory et al. 2003), while the GAFb domain of PDE2 binds cAMP (Martinez et al. 2002b). The tandem GAF domains of CyaB2 have also been shown to be highly specific for cAMP as monitored by the activation of the CyaB1-CyaB2 fusion protein (Bruder et al. 2005). However, we observed that cGMP could efficiently compete with cAMP for binding to the isolated GAFb domain, with an IC_{50} $7.6 \pm 1.9 \mu\text{M}$ (Fig. 1C), in contrast to the specificity of nucleotide-mediated activation of the adenylyl cyclase domain fused to the tandem GAF domains of CyaB2 (Bruder et al. 2005).

To make a direct comparison of binding specificity, we performed cyclic nucleotide binding assays with a construct containing both the GAF domains. For this, a GST fusion of the tandem GAFab domains encompassing residues S77 to L431 was expressed and purified. Competition radiolabeled nucleotide binding assays with cAMP and cGMP revealed that the tandem GAFab

domain show much higher affinity for cAMP (IC_{50} $0.05 \pm 0.02 \mu M$; 16-fold higher affinity than the isolated GAFb domain) and a much reduced affinity for cGMP (IC_{50} $2651 \pm 870 \mu M$; 348-fold lower affinity compared to the isolated GAFb domain) (Fig. 1D). Therefore, while the isolated GAFb domain showed only 10-fold selectivity towards cAMP, the tandem GAFab domain showed much higher (~50, 000-fold) selectivity for cAMP. Thus, although nucleotide binding is preserved in the isolated GAFb domain, removal of the associated GAFa domain results in a reduction in both affinity and specificity of nucleotide binding.

Cyclic GMP binds to the GAFb domain of CyaB2 in a mode distinct from that of cAMP

To gain insight into the mechanism by which cGMP could interact with the isolated GAFb domain, we performed *in silico* docking of cGMP on the structure of the GAFb domain. We removed the bound cAMP molecule from the crystal structure of the GAFb domain and used it as the receptor (Martinez et al. 2005), and all dockings were performed using AutoDock (Morris 1998). We first tested the performance of the *in silico* experiment by docking cAMP and comparing the results with the original crystal structure data. Indeed, cAMP could be docked into the GAFb domain in a pose closely mimicking the original structure, with an RMSD of $\sim 0.2 \text{ \AA}$ between the docked and crystallized cAMP molecule. Following this, we performed a blind docking of cGMP molecule with 20 independent docking runs that resulted in the same number of final docked conformers. All the cGMP conformers except one were docked into the cNMP binding pocket of the GAFb domain (Fig. 2B). Interestingly, the majority of the conformers were found to interact with the GAFb domain in an orientation that was distinct from cAMP (designated as mode 1) while only two conformers were found to interact in a mode that was similar to crystal structure bound cAMP (designated as Mode 2) (Fig. 2A & B). Further, the energy of interaction was lower for mode 1 conformers compared to mode 2 conformers.

Detailed analysis of a representative mode 1 conformer revealed that this type of conformation could be stabilized by H-bond interactions of the O6 of cGMP with the side chain of Asn 359, and N7 with Asp 356 present in the helix $\alpha 4$. Therefore, *in silico* docking studies suggested that the mode of binding of cGMP was distinct from that seen for cAMP.

Analysis of the crystal structure of GAFb domain showed an interaction between the side chain of I308 and the adenosine ring of cAMP (Martinez et al. 2005). An equivalent interaction is found to be conserved in cyclic nucleotide binding GAF domains (Fig. 2C). However, based on our docking results, this interaction appears to be dispensable for cGMP binding, (Fig. 2A). Therefore, we mutated the Ile 308 to A (I308A mutant), and performed radiolabeled ligand binding assays with the purified mutant GAFb domain. We observed an expected ~50% reduction in the binding of ^3H -cAMP to the I308A mutant GAFb domain (Fig. 2D), correlated with a reduced affinity for cAMP (Fig. 2E & G). However, as predicted from the structural analysis of the docked cGMP conformations, the affinity for cGMP remained unaltered in this mutant protein (Fig. 2F & G), indicating that cGMP does indeed bind to the GAFb domain in a distinct mode.

Ligand induced structural changes in the GAF domain are subtle and cannot be detected by BRET

Ligand binding to the GAF domains in CyaB2 is highly cooperative (Bruder et al. 2005) and acts as an allosteric signal that results in the activation of the C-terminal adenylyl cyclase domain (Kanacher et al. 2002). This implies that ligand binding to the GAFb domain may result in a structural change that is communicated to both the N-terminal GAFa domain and the C-terminal adenylyl cyclase domain (Fig. 1A). We utilized BRET technology to determine if ligand binding

1 to the GAFb domain results in a significant structural rearrangement. We have earlier used this
2 strategy successfully to detect cGMP-induced structural changes in the isolated GAFa domain of
3 PDE5 (Biswas et al. 2008), as well as in the full-length PDE5 (Biswas & Visweswariah 2011).

4 We generated a fusion protein containing the GFP² protein at the N-terminal and Rluc protein to
5 the C-terminal (GAFb sensor) (Fig. 3A). The GAFb sensor protein was expressed in HEK293T
6 cells and the expression was monitored by western blot analysis antibodies to Rluc (Fig. 3B).

7 Lysates prepared from HEK293T cells expressing the GAFb sensor were incubated in the
8 absence or presence of 1 mM cAMP or cGMP, and BRET was measured. We used the F163A
9 mutant GAFa domain of PDE5, which binds both cAMP and cGMP, for the purpose of
10 comparison (Biswas et al. 2008). A basal BRET ratio of the GAFb sensor could be detected,
11 (Fig. 3C), indicating that the GAFb sensor expressed in mammalian cells is folded and could
12 potentially bind ligand. Importantly, unlike the PDE5 GAFa(F163A) sensor which showed an
13 increase in the BRET ratio in the presence of both cAMP and cGMP, no change in the BRET
14 ratio was observed for the GAFb sensor in the presence of either cAMP or cGMP (Fig. 3C).

15
16 To rule out the requirement of any cellular factor for the induction of structural changes in the
17 GAF domain, we performed experiments with live cells expressing the GAFb sensor.

18 Intracellular levels of cAMP were elevated using forskolin, (Litosch et al. 1982), and
19 intracellular cGMP levels were increased by treating cells with sodium nitroprusside (SNP)
20 (Murad 1986). Although both forskolin and SNP treatment resulted in increased intracellular
21 levels of cAMP and cGMP respectively, no significant changes were observed in the BRET
22 ratios (Fig. 3D & 3E)

1 The lack of change in BRET may indicate that either there is no substantial structural change
2 induced in the GAFb domain on ligand binding, or the change in conformation induced by ligand
3 binding could not be detected due to lack of a specific structural element in the construct used for
4 BRET (Russwurm et al. 2007). We therefore generated fusion constructs containing either the
5 tandem GAFab domains or the tandem GAFab domains along with the complete N-terminal
6 region of CyaB2 (called as GAFab and NterGAFab sensors, respectively). Expression levels of
7 these proteins were lower than that of the isolated GAFb domain (Fig. 3B), and the basal BRET
8 of the constructs decreased in the order GAFb > GAFab > NterGAFab (Fig. 3C). This change in
9 the basal BRET ratio suggested that we were able to detect spatial positioning of GFP² and Rluc
10 in the sensor constructs. However, incubation of lysates prepared from cells expressing either
11 the GAFab or the NterGAFab sensor with cAMP or cGMP (1 mM) also did not result in a
12 significant alteration in the BRET (Fig. 3C).

13 **Distinct changes in the dynamics of the GAFb domain of CyaB2 induced by cAMP and** 14 **cGMP binding**

15 The lack of observable change in the BRET of the GAF domains of CyaB2 on ligand binding
16 was intriguing. We therefore decided to monitor more subtle structural changes in the GAFb
17 domain at a higher resolution using amide hydrogen/deuterium exchange mass spectrometry
18 (HDXMS). His₆-tagged GAFb domain was expressed in bacteria and purified for use in these
19 experiments. Complete pepsin digestion of the protein under deuterium exchange quench
20 conditions (pH = 2.5) resulted in the generation of multiple peptide fragments across the domain
21 with >90% sequence coverage (Fig. 4), thus providing a detailed overview of the solvent
22 accessibility and dynamics of the GAFb domain at peptide resolution.

A comparison of amide exchange of various peptides in the absence and presence of cAMP showed a decrease in exchange at the central core region comprising the ligand-binding pocket (Fig. 4A), suggesting a ‘closing’ of the ‘open’ ligand binding pocket of the GAFb domain. These include peptide (305-317) spanning parts of $\beta 1$ and $\beta 2$ sheets and $\beta 1$ - $\beta 2$ loop showed lower dynamics in the presence of cAMP. The peptide (305-317) contains two residues that interact with cAMP, namely Ile 308 and Thr 309. As discussed previously, Ile 308 provides hydrophobic stacking interaction to cAMP while Thr 309 interacts with the N6 of cAMP, forming H-bond through the peptide backbone carbonyl oxygen. Interestingly, cAMP binding resulted in an increased solvent accessibility of peptides arising from the N- and C-terminal helices. The N-terminal $\alpha 2$ helix connects the GAFb domain to the GAFa domain, and the C-terminal $\alpha 5$ helix connects the GAFb domain to the catalytic adenylyl cyclase domain of CyaB2. This suggests that the structural changes observed here are signatures of allosteric signal transduction from the GAFb domain to both the GAFa and the adenylyl cyclase domain. The absence of any change in the BRET signal observed with the GAFb sensor construct indicates that the increase in amide exchange following cAMP binding arose from an increase in the entropy of these parts of the GAFb domain, and not as a consequence of a gross change in the relative structure of the protein. Binding of cGMP, on the other hand, resulted in remarkably less changes in the amide exchange of the GAFb domain, and only some regions in the ligand-binding pocket showed an increase in exchange compared to the unliganded protein (Fig. 4B). A comparison of the exchange profile of the GAFb domain in the presence of cAMP and cGMP clearly showed a number of differences (Fig. 4C), especially in the region containing peptide (305-317) harboring the residue I308. This is in agreement with direct cyclic nucleotide ligand binding data, and confirmed that indeed cAMP and cGMP bind to the GAFb domain in distinct modes. In addition, a lack of alteration in

the dynamics of the terminal helices in the presence of cGMP provides a structural basis for the lack of allosteric regulation induced by cGMP binding to the GAFb domain (Bruder et al. 2005).

DISCUSSION

Most cyclic nucleotide binding GAF domains are specific in terms of ligand binding. Efforts have been directed towards understanding the mechanism by which these domains achieve specificity. Mutational and biochemical analysis of GAF domains from other proteins have provided some understanding of the mechanism by which these structurally similar domains discriminate nucleotides (Linder et al. 2007; Schultz 2009). We propose that in addition to the specific interaction of certain residues with the chemical groups present in nucleotides, the hydrophobic interaction provided by residue equivalent to I308 help GAF domains in selecting a specific cyclic nucleotide. Mutations equivalent to I308A in the GAFa domain of PDE5 (Sopory et al. 2003) and the GAFb domain of PDE2 (Wu et al. 2004) has been shown to reduce cGMP affinity, while affinity for cAMP were reported to be largely unaffected. The GAFa domain of PDE5 and the GAFb domain of PDE2 are known to bind cGMP with high affinity while the affinity of these GAF domains is much less for cAMP. Thus, it appears that the I308 residue in cyclic nucleotide-binding GAF domains dictates the binding of the high affinity ligand. Importantly we show here that a low affinity ligand binds in a different mode, since mutation of I308 only marginally reduced the affinity of binding of cGMP to the Cya GAFb domain (Fig. 2C).

The crystal structure of the cAMP-bound GAFb domain showed that cAMP is largely buried, leading to the speculation that the ligand binding pocket is initially present in an open conformation ready to receive the ligand (Martinez et al. 2005). Reduction in the dynamics of peptides spanning the ligand-binding pocket (helix α 4, helix α 3 and sheet β 3) in the presence of

1 cAMP confirms that the domain ‘closes’ on ligand binding. A similar mechanism has been
2 proposed for the GAFa domain of PDE5 on binding cGMP (Wang et al. 2010). Interestingly, it
3 appears that the mode of how the ‘open’ GAF domain ‘closes’ on binding either the low affinity
4 or high affinity ligand is different, as observed in our docking, mutational and HDXMS analysis.
5 This kind of structural adaptation could be necessary to avoid steric hindrance but retain
6 interactions between the GAF domain and the ligand. This structural plasticity could also play a
7 role in the way the allosteric signal of ligand binding to the GAF domain is transferred to the C-
8 terminal catalytic domain.

9 In addition to the mechanism of ligand specificity by a specific residue in the ligand-binding site,
10 comparison of ligand binding to the isolated GAFb domain and the tandem GAF domains
11 revealed a much higher degree of ligand selectivity. This indicates that the isolated GAFb
12 domain and the tandem GAF domains are structurally and biochemically different. Proteins exist
13 in an ensemble of conformations at steady state. The presence of the second GAF domain could
14 influence ligand-binding behavior of the associated GAFb domain by establishing new steady
15 state conformations, allowing concomitant ligand binding specificity, coupled with precise
16 ligand-induced allosteric regulation of these proteins.

18 CONCLUSION

19 Our results identify the basis of nucleotide selectivity and proximal conformational changes that
20 occur following cAMP binding to the GAFb domain of CyA2. They may also allow a molecular
21 understanding of the ‘regulated unfolding’ that needs to occur during activation of the C-terminal
22 catalytic domains associated with the GAF domains (Schultz & Natarajan 2013) , and also

provide a foundation for the design of molecules that could regulate GAF domain function and action.

AUTHOR CONTRIBUTION

All authors designed experiments. KHB and SB performed experiments. KHB, GSA and SSV analyzed and interpreted data and wrote the paper.

FUNDING SOURCES

Funding has been provided by the Department of Biotechnology (SSV) and a fellowship from the Council for Scientific and Industrial Research (KHB), Government of India. Support was also provided by the Mechanobiology Institute, National University of Singapore (NUS), Singapore and Waters Center of Innovation Program (to GSA). Support for personnel exchanges between laboratories was from the NUS-India Research Initiative. KHB is currently supported by a Research Fellowship from the Mechanobiology Institute, NUS, Singapore.

REFERENCES

- Anantharaman V, Koonin EV, and Aravind L. 2001. Regulatory potential, phyletic distribution and evolution of ancient, intracellular small-molecule-binding domains. *J Mol Biol* 307:1271-1292.
- Aravind L, Mazumder R, Vasudevan S, and Koonin EV. 2002. Trends in protein evolution inferred from sequence and structure analysis. *Curr Opin Struct Biol* 12:392-399.
- Aravind L, and Ponting CP. 1997. The GAF domain: an evolutionary link between diverse phototransducing proteins. *Trends Biochem Sci* 22:458-459.
- Badireddy S, Yunfeng G, Ritchie M, Akamine P, Wu J, Kim CW, Taylor SS, Qingsong L, Swaminathan K, and Anand GS. 2011. Cyclic AMP analog blocks kinase activation by stabilizing inactive conformation: conformational selection highlights a new concept in allosteric inhibitor design. *Mol Cell Proteomics* 10:M110 004390.
- Bakre MM, Ghanekar Y, and Visweswariah SS. 2000a. Homologous desensitization of the human guanylate cyclase C receptor. Cell-specific regulation of catalytic activity. *Eur J Biochem* 267:179-187.
- Bakre MM, Sopory S, and Visweswariah SS. 2000b. Expression and regulation of the cGMP-binding, cGMP-specific phosphodiesterase (PDE5) in human colonic epithelial cells: role in the induction of cellular refractoriness to the heat-stable enterotoxin peptide. *J Cell Biochem* 77:159-167.
- Bateman RH, Carruthers R, Hoyes JB, Jones C, Langridge JJ, Millar A, and Vissers JP. 2002. A novel precursor ion discovery method on a hybrid quadrupole orthogonal acceleration time-of-flight (Q-TOF) mass spectrometer for studying protein phosphorylation. *J Am Soc Mass Spectrom* 13:792-803.

- 1 Biswas KH, Sopory S, and Visweswariah SS. 2008. The GAF domain of the cGMP-binding,
2 cGMP-specific phosphodiesterase (PDE5) is a sensor and a sink for cGMP. *Biochemistry*
3 47:3534-3543.
- 4 Biswas KH, and Visweswariah SS. 2011. Distinct allostery induced in the cyclic GMP-binding,
5 cyclic GMP-specific phosphodiesterase (PDE5) by cyclic GMP, sildenafil, and metal
6 ions. *J Biol Chem* 286:8545-8554.
- 7 Bruder S, Linder JU, Martinez SE, Zheng N, Beavo JA, and Schultz JE. 2005. The
8 cyanobacterial tandem GAF domains from the cyaB2 adenylyl cyclase signal via both
9 cAMP-binding sites. *Proc Natl Acad Sci U S A* 102:3088-3092.
- 10 Bruder S, Schultz A, and Schultz JE. 2006. Characterization of the tandem GAF domain of
11 human phosphodiesterase 5 using a cyanobacterial adenylyl cyclase as a reporter enzyme.
12 *J Biol Chem* 281:19969-19976.
- 13 Charbonneau H, Prusti RK, LeTrong H, Sonnenburg WK, Mullaney PJ, Walsh KA, and Beavo
14 JA. 1990. Identification of a noncatalytic cGMP-binding domain conserved in both the
15 cGMP-stimulated and photoreceptor cyclic nucleotide phosphodiesterases. *Proc Natl*
16 *Acad Sci U S A* 87:288-292.
- 17 Finn RD, Mistry J, Tate J, Coggill P, Heger A, Pollington JE, Gavin OL, Gunasekaran P, Ceric
18 G, Forslund K, Holm L, Sonnhammer EL, Eddy SR, and Bateman A. 2010. The Pfam
19 protein families database. *Nucleic Acids Res* 38:D211-222.
- 20 Geromanos SJ, Vissers JP, Silva JC, Dorschel CA, Li GZ, Gorenstein MV, Bateman RH, and
21 Langridge JJ. 2009. The detection, correlation, and comparison of peptide precursor and
22 product ions from data independent LC-MS with data dependant LC-MS/MS. *Proteomics*
23 9:1683-1695.

- 1 Heikaus CC, Pandit J, and Klevit RE. 2009. Cyclic nucleotide binding GAF domains from
2 phosphodiesterases: structural and mechanistic insights. *Structure* 17:1551-1557.
- 3 Heikaus CC, Stout JR, Sekharan MR, Eakin CM, Rajagopal P, Brzovic PS, Beavo JA, and Klevit
4 RE. 2008. Solution structure of the cGMP binding GAF domain from phosphodiesterase
5 5: insights into nucleotide specificity, dimerization, and cGMP-dependent conformational
6 change. *J Biol Chem* 283:22749-22759.
- 7 Kanacher T, Schultz A, Linder JU, and Schultz JE. 2002. A GAF-domain-regulated adenylyl
8 cyclase from *Anabaena* is a self-activating cAMP switch. *Embo J* 21:3672-3680.
- 9 Li GZ, Vissers JP, Silva JC, Golick D, Gorenstein MV, and Geromanos SJ. 2009. Database
10 searching and accounting of multiplexed precursor and product ion spectra from the data
11 independent analysis of simple and complex peptide mixtures. *Proteomics* 9:1696-1719.
- 12 Linder JU, Bruder S, Schultz A, and Schultz JE. 2007. Changes in purine specificity in tandem
13 GAF chimeras from cyanobacterial *cyaB1* adenylyl cyclase and rat phosphodiesterase 2.
14 *Febs J* 274:1514-1523.
- 15 Litosch I, Hudson TH, Mills I, Li SY, and Fain JN. 1982. Forskolin as an activator of cyclic
16 AMP accumulation and lipolysis in rat adipocytes. *Mol Pharmacol* 22:109-115.
- 17 Martinez SE, Beavo JA, and Hol WG. 2002a. GAF domains: two-billion-year-old molecular
18 switches that bind cyclic nucleotides. *Mol Interv* 2:317-323.
- 19 Martinez SE, Bruder S, Schultz A, Zheng N, Schultz JE, Beavo JA, and Linder JU. 2005. Crystal
20 structure of the tandem GAF domains from a cyanobacterial adenylyl cyclase: modes of
21 ligand binding and dimerization. *Proc Natl Acad Sci U S A* 102:3082-3087.

- 1 Martinez SE, Wu AY, Glavas NA, Tang XB, Turley S, Hol WG, and Beavo JA. 2002b. The two
2 GAF domains in phosphodiesterase 2A have distinct roles in dimerization and in cGMP
3 binding. *Proc Natl Acad Sci U S A* 99:13260-13265.
- 4 Morris GM, Goodsell, D. S., Halliday, R.S., Huey, R., Hart, W. E., Belew, R. K. and Olson,
5 A. J. 1998. Automated Docking Using a Lamarckian Genetic Algorithm and and
6 Empirical Binding Free Energy Function. *J Computational Chemistry* 19:1639-1662.
- 7 Murad F. 1986. Cyclic guanosine monophosphate as a mediator of vasodilation. *J Clin Invest*
8 78:1-5.
- 9 Nambi S, Basu N, and Visweswariah SS. 2010. cAMP-regulated protein lysine acetylases in
10 mycobacteria. *J Biol Chem* 285:24313-24323.
- 11 Pandit J, Forman MD, Fennell KF, Dillman KS, and Menniti FS. 2009. Mechanism for the
12 allosteric regulation of phosphodiesterase 2A deduced from the X-ray structure of a near
13 full-length construct. *Proc Natl Acad Sci U S A* 106:18225-18230.
- 14 Russwurm M, Mullershausen F, Friebe A, Jager R, Russwurm C, and Koesling D. 2007. Design
15 of fluorescence resonance energy transfer (FRET)-based cGMP indicators: a systematic
16 approach. *Biochem J* 407:69-77.
- 17 Russwurm M, Schlicker C, Weyand M, Koesling D, and Steegborn C. 2011. Crystal structure of
18 the GAF-B domain from human phosphodiesterase 5. *Proteins* 79:1682-1687.
- 19 Schultz J. 2009. Structural and Biochemical Aspects of Tandem GAF Domains. In: Schmidt
20 HHW, Hofmann F, and Stasch J-P, eds. *cGMP: Generators, Effectors and Therapeutic*
21 *Implications*: Springer Berlin Heidelberg, 93-109.
- 22 Schultz JE, and Natarajan J. 2013. Regulated unfolding: a basic principle of intraprotein
23 signaling in modular proteins. *Trends Biochem Sci* 38:538-545.

- 1 Schuttelkopf AW, and van Aalten DM. 2004. PRODRG: a tool for high-throughput
2 crystallography of protein-ligand complexes. *Acta Crystallogr D Biol Crystallogr*
3 60:1355-1363.
- 4 Shen Z, Li P, Ni RJ, Ritchie M, Yang CP, Liu GF, Ma W, Liu GJ, Ma L, Li SJ, Wei ZG, Wang
5 HX, and Wang BC. 2009. Label-free quantitative proteomics analysis of etiolated maize
6 seedling leaves during greening. *Mol Cell Proteomics* 8:2443-2460.
- 7 Shenoy AR, and Visweswariah SS. 2003. Site-directed mutagenesis using a single mutagenic
8 oligonucleotide and DpnI digestion of template DNA. *Anal Biochem* 319:335-336.
- 9 Silva JC, Denny R, Dorschel CA, Gorenstein M, Kass IJ, Li GZ, McKenna T, Nold MJ,
10 Richardson K, Young P, and Geromanos S. 2005. Quantitative proteomic analysis by
11 accurate mass retention time pairs. *Anal Chem* 77:2187-2200.
- 12 Sopory S, Balaji S, Srinivasan N, and Visweswariah SS. 2003. Modeling and mutational analysis
13 of the GAF domain of the cGMP-binding, cGMP-specific phosphodiesterase, PDE5.
14 *FEBS Lett* 539:161-166.
- 15 Wales TE, Fadgen KE, Gerhardt GC, and Engen JR. 2008. High-speed and high-resolution
16 UPLC separation at zero degrees Celsius. *Anal Chem* 80:6815-6820.
- 17 Wang H, Robinson H, and Ke H. 2010. Conformation changes, N-terminal involvement, and
18 cGMP signal relay in the phosphodiesterase-5 GAF domain. *J Biol Chem* 285:38149-
19 38156.
- 20 Weis DD, Engen JR, and Kass IJ. 2006. Semi-automated data processing of hydrogen exchange
21 mass spectra using HX-Express. *J Am Soc Mass Spectrom* 17:1700-1703.

- 1 Wu AY, Tang XB, Martinez SE, Ikeda K, and Beavo JA. 2004. Molecular determinants for
2 cyclic nucleotide binding to the regulatory domains of phosphodiesterase 2A. *J Biol*
3 *Chem* 279:37928-37938.
- 4 Zoraghi R, Corbin JD, and Francis SH. 2004. Properties and functions of GAF domains in cyclic
5 nucleotide phosphodiesterases and other proteins. *Mol Pharmacol* 65:267-278.




Fig. 1 Isolated GAFb domain binds both cAMP and cGMP. [A] Cartoon representation of the structure of the GAFb domain illustrating various secondary structure elements and bound cAMP molecule [PDB: 1YKD (Martinez et al. 2005)]. [B] Proteins ($\sim 1 \mu\text{g}$) bound to glutathione beads were incubated with $^3\text{H-cAMP}$ ($\sim 1 \text{ nM}$) in the absence or presence of $10 \mu\text{M}$ unlabeled cAMP. Data shown is a representative of assays performed thrice in duplicate, and values shown are mean $\pm$ S. E. M. The inset shows a Coomassie stained gel picture of the purified proteins used in the assay. [C] & [D] Purified GST-GAFb [C] or GST-GAFa-GAFb [D] proteins bound to beads were incubated with $\sim 1 \text{ nM}$ $^3\text{H-cAMP}$ and increasing concentration of unlabeled cAMP or cGMP. Data shown is mean $\pm$ S. E. M of duplicate determinations and is representative of independent assays.




Fig. 2 GAFb domain binds cGMP in a distinct mode. [A] Cartoon representation of the GAFb domain [PDB: 1YKD (Martinez et al. 2005)] with docked cAMP and cGMP conformers. Inset shows zoomed in view of the ligand binding pocket of GAFb with two different clusters of docked cGMP conformers indicated as cGMP-1 and cGMP-2. Side chain of I308 is also shown for comparison with different ligand molecules. [B] Distribution of docked cGMP conformers obtained clustering with an RMSD of 0.5 Å. Mode 1 represents the cluster with maximum number of conformers and with lowest energy while mode 2 represents the cluster with cGMP docked in a way that mimics bound cAMP. Third cluster consisting of one conformer out of 20 was docked outside the ligand-binding pocket and therefore, has not been shown. [C] Conserved interaction between high affinity ligand, either cAMP or cGMP, with the residue equivalent to I308 in different cyclic nucleotide binding GAF domains (GAFb domain of CyaB2 – cAMP [PDB: 1YKD]; GAFb domain of PDE2 – cGMP [PDB: 1MCO]; GAFa domain of PDE5 – cGMP [PDB: 2K31]; GAFb domain of PDE10 – cAMP [PDB: 2E4S]; GAFa domain of PDE6 –

1 cGMP [PDB: 3DBA]. [D] Either wild type (WT) or the I308A mutant GST-fusion proteins (~1
2 µg) bound to glutathione beads were incubated with ³H-cAMP (~1 nM) in the absence or
3 presence of 10 µM unlabeled cAMP. Data shown is a representative of assays performed twice in
4 duplicate, and values shown are mean ± S. E. M. The inset shows a Coomassie stained gel
5 picture of the purified proteins used in the assay. [E] & [F] Purified wild type and I308A mutant
6 GST fusion proteins bound to beads were incubated with ~1 nM ³H-cAMP and increasing
7 concentration of unlabeled cAMP [E] or cGMP [F]. Data shown is mean ± S. E. M of duplicate
8 determinations and is representative of independent assays. [G] Logarithm of IC₅₀ values
9 obtained for the wild type and I308A mutant protein with either cAMP or cGMP were plotted.
10 Data shown is mean ± S. E. M. of IC₅₀ values determined from multiple independent assays.




Fig. 3 Ligand binding to the GAFb domain does not result in structural changes at the N- and C-termini. [A] Diagrammatic representation of various BRET-based sensor constructs used in the study. [B] Western blot analysis using anti-Rluc polyclonal antibody to confirm the expression of GAFb, GAFab and NterGAFab sensor constructs. Expected molecular weight of the GAFb, GAFab and NterGAFab sensor constructs are 82.7, 103.8 and 112.7 kDa, respectively. [C] Lysates prepared from cells expressing the PDE5 GAFa(F163A), GAFb, GAFab and NterGAFab sensor constructs were incubated in the absence or presence of 1 mM cAMP or cGMP at 37 °C for 10 min followed by BRET measurement. [D & E] HEK293T cells transfected with the GAFb sensor were treated with 100 μ M of either forskolin (5 min) [D] or SNP (2 min) [E] at 37 °C and BRET was determined. Intracellular levels of cAMP or cGMP

1 were determined using parallel set of cells. Data shown are mean $\pm$ S.E.M from a representative
 2 experiment performed in triplicate.

3

4




Fig. 4 Protein-wide overview of structural changes induced in the GAFb domain of CyaB2

on ligand binding. Absolute difference in numbers of deuterons (inferred from difference in mass in Daltons (Da) (y axis) between free and cAMP-bound (top), free and cGMP-bound (middle) and cAMP- and cGMP-bound (bottom) states is plotted for each pepsin digest fragment listed from the N- to C-terminus (x axis) of GAFb domain for each deuterium exchange time point in a difference plot. Time = 0.5 min (orange), 2 min (red), 5 min (blue) and 10 min (black). Shifts in the positive scale represent increases in deuterium exchange and shifts in the negative scale represent decreases in deuterium exchange. A difference of 0.5 Da is considered significant (dashed red line). Plots were generated using the software DYNAMX (Ver. 2.0 Waters). Each point represents a pepsin digest fragment.